This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A D-Retro-Inverso peptidomimetic designed to disrupt the FOXO4-p53 survival signal that keeps senescent cells ("zombie cells") alive. By freeing p53 to initiate apoptosis, FOXO4-DRI selectively clears cells that have stopped dividing but continue to secrete inflammatory signals — the senescence-associated secretory phenotype (SASP) linked to tissue aging and functional decline. Studied in mouse models; no human trials conducted.
FOXO4-DRI is an early-stage research compound. The primary evidence base is a single landmark study in mice (Baar et al., Cell 2017). No human clinical trials have been completed. Dosing references are extrapolated from mouse data. This is one of the most scientifically compelling compounds in longevity research — and also one of the least validated in humans. We describe the evidence accurately; researchers should weigh that distinction carefully.
Cellular senescence is a normal biological process: cells that are damaged, stressed, or have reached their replication limit are supposed to exit the cell cycle permanently and then be cleared by the immune system. The problem is that clearance becomes less efficient with age, and senescent cells accumulate. They stop dividing — but they don't stop working. Instead, they secrete a chronic inflammatory cocktail of cytokines, proteases, and growth factors called the SASP (senescence-associated secretory phenotype) that damages neighboring healthy cells and drives systemic low-grade inflammation.
FOXO4 is a transcription factor that senescent cells upregulate as a survival mechanism. It interacts with p53 and sequesters it in a complex that prevents p53 from triggering the cell's own apoptosis (programmed death). In normal cells, this interaction is minimal — FOXO4 is not strongly expressed. In senescent cells, it is the latch that keeps them alive when they should be cleared.
FOXO4-DRI is a mirror-image (D-amino acid, retro-inverso) version of the FOXO4 helical domain that competes for p53 binding. By occupying the p53 binding site, it disrupts the survival complex — freeing p53 to trigger apoptosis specifically in cells where FOXO4 is highly expressed. Normal cells, which don't upregulate FOXO4, are largely unaffected.
Old mice treated with FOXO4-DRI showed significant improvements in grip strength, running endurance, and exercise capacity compared to untreated age-matched controls. Functional decline reversed, not just slowed.
Markers of kidney function improved in treated mice. Glomerular damage (a hallmark of renal aging) was reduced in association with senescent cell clearance from renal tissue — suggesting organ-level benefit beyond musculoskeletal endpoints.
Treated mice recovered fur density lost to chemotherapy-induced senescence. One of the visual endpoints that made the 2017 Cell paper widely reproduced — a striking external signal of senolytic activity in the skin.
Mice treated with FOXO4-DRI following chemotherapy (which induces large-scale cellular senescence) recovered faster and showed better tissue regeneration than controls. Positioned as an adjunct to chemotherapy in this research context.
Inflammatory cytokine levels — the SASP signature — fell measurably after FOXO4-DRI treatment as senescent cells were cleared. Reduced systemic inflammation is the mechanistic link to all downstream tissue benefits.
Critically: normal (non-senescent) cells were not meaningfully affected in the study. Selectivity for FOXO4-high cells appears robust in mouse models. Whether this holds across human tissue types is an open research question.
Baar et al., Cell 169(1):132-147. The single most-cited source for FOXO4-DRI. Rigorous animal study; the paper is genuine and replicable. Human extrapolation remains speculative.
No registered human trials for FOXO4-DRI have been completed. Dosing protocols referenced in the research community are extrapolated from mouse mg/kg data — not human pharmacokinetics.
D-Retro-Inverso engineering makes FOXO4-DRI resistant to endogenous proteases — a critical design feature that allows the peptidomimetic to survive long enough to reach intracellular targets.
Human dosing for FOXO4-DRI is extrapolated from the mouse study dose of 5mg/kg. Applying standard allometric scaling to a 70–80kg human yields a reference dose in the 1–2mg range. The research community commonly uses intermittent (pulse) dosing rather than daily administration — consistent with the senolytic model where periodic clearance bursts are followed by rest. Subcutaneous injection is standard.
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Pulse (standard) | 1–2mg SC | 3 consecutive days, then off 4+ weeks | Most referenced human research protocol. Mirrors the pulse approach used in mouse studies. Long off-period allows immune clearance of apoptosed cells. |
| Conservative start | 0.5mg SC | 3 consecutive days, then off 6 weeks | Lower dose for initial research assessment. Dose is based on extrapolated mouse data; individual response at human scale is unknown. |
| Frequency caveat | — | — | Senolytics are not daily-use compounds. The rationale is periodic clearance, not chronic pathway activation. Over-frequent dosing has no added benefit in the mouse model and may carry unknown risks. |
FOXO4-DRI is most naturally combined with other longevity-oriented research compounds. It is typically cycled intermittently rather than stacked continuously.
10mg vials. Finnrick-verified purity, lot-specific COA, ships in 24 hours. One of the most experimental compounds in our longevity catalog.
Begin Protocol Intake View All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.